Accel Research Sites featured in CNBC article about Pfizer vaccine effectiveness in children - Alcanza Clinical Research

Create a Profile

I accept digital forms of communication(Required)
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is for validation purposes and should be left unchanged.

Create a Profile

I accept digital forms of communication(Required)
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is for validation purposes and should be left unchanged.

Get In Touch Mobile

I accept digital forms of communication(Required)
This field is for validation purposes and should be left unchanged.

FIND A TRIAL NEAR YOU

No location found for this Zip Code

-- or --

No location found for this Location

FIND A TRIAL NEAR YOU

No location found for this Zip Code

-- or --

No location found for this Location
Back
Date Published: 10/27/2021

Accel Research Sites featured in CNBC article about Pfizer vaccine effectiveness in children

The CDC has reported positive numbers regarding Pfizer’s pediatric COVID-19 vaccine for children ages 12 to 18 years old.

The CDC found the vaccine is over 93% effective against hospitalization for that age group.

Dr. Salma Elfaki was a part of several pediatric COVID-19 vaccine clinical trials and was featured seeing a patient in a photo in the article.

See it here.

Back

Ready to be part of healthcare history? Find the right clinical trial for you.

Get In Touch

I accept digital forms of communication(Required)
This field is for validation purposes and should be left unchanged.
Accessibility Adjustment

Color Adjustment

Orientation Adjustment

Font Size

 

Line height